James Auran, MD, a professor of ophthalmology at Columbia University Irving Medical Center and president of the American Society of Ophthalmic Trauma, outlines the benefits and challenges of transferring ophthalmic care to outpatient facilities.
Transitioning to an outpatient model provides opportunities for savings and efficiency, said James Auran, MD, a professor of ophthalmology at Columbia University Irving Medical Center and president of the American Society of Ophthalmic Trauma.
Transcript
As ophthalmology has evolved into an outpatient specialty over the past few decades, what challenges have come along with this transition?
I wouldn't look at it so much as challenges, as much as the incredible opportunities for cost savings, for efficiency, and for just making it a more patient-friendly environment. I think it's been a tremendous advance. I've seen very few downsides, although there is one small one with trauma which we could go into. Ophthalmologists, in general, have shied away from caring for trauma. It's disruptive to your practice to have a patient come in who needs immediate care, especially if it's complex. The skill set involved is specialized, and it's not something you want to do once every 2 years. When doctors were hospital-based, it was a little bit more, it'd be more common in their practice to encounter this. The trend toward being in private office groups and in surgery centers has sort of put a lot of eye doctors out of touch with trauma care.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Targeted Treatment May Improve Outcomes in IDH1-Mutated MDS
January 13th 2025A pair of abstracts presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exhibition suggest that IDH1-targeted treatment may improve survival among patients with myelodysplastic syndromes (MDS) with the mutation.
Read More